Earnings Summary

Novo Nordisk A/s’s revenue jumped 36.95% since last year same period to $65863Mn in the Q4 2023. On a quarterly growth basis, Novo Nordisk A/s has generated 12.14% jump in its revenue since last 3-months.

Novo Nordisk A/s’s net profit jumped 61.59% since last year same period to $21963Mn in the Q4 2023. On a quarterly growth basis, Novo Nordisk A/s has generated -2.29% fall in its net profits since last 3-months.

Novo Nordisk A/s’s net profit margin jumped 17.99% since last year same period to 33.35% in the Q4 2023. On a quarterly growth basis, Novo Nordisk A/s has generated -12.87% fall in its net profit margins since last 3-months.

Novo Nordisk A/s’s earning per share (EPS) estimates for the current quarter stand at 0.78 - a -82.56% fall from last quarter’s estimates.

Novo Nordisk A/s’s earning per share (EPS) estimates for the current year stand at 0.78.

Novo Nordisk A/s’s earning per share (EPS) fell -100% since last year same period to 0 in the Q1 2024. This indicates that the Novo Nordisk A/s has generated -100% annual rate of fall in its earning per share (EPS) in the last 4 quarters.

Novo Nordisk A/s declared 0.93 dividend per share during the earnings announcement for Q1 2024.